Grant Number:	5R01CA255809-02 Interpret this number
Primary Investigator:	Yuan, Jian-Min
Organization:	University Of Pittsburgh At Pittsburgh
Project Title:	Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes
Fiscal Year:	2022

ABSTRACT The incidence rate of hepatocellular carcinoma in the United States has been increasing in the past several decades. Non-alcoholic fatty liver disease has become the most important risk factor for hepatocellular carcinoma. About 25 percent of adults in the United Stated have non-alcoholic fatty liver disease, which includes a spectrum of liver diseases from simple steatosis, non-alcoholic steatohepatitis to fibrosis and cirrhosis. Liver fibrosis has been recognized as the key determinant of the risk of long-term health outcome for patients with non-alcoholic fatty liver disease, which will soon be the most common indication for liver transplantation in the United States. Currently there is no effective treatment or prevention strategy for non-alcoholic fatty liver disease. It is an urgently unmet need to identify novel biological and environmental factors that drive the progression of non-alcoholic fatty liver disease to the development of hepatocellular carcinoma and end-stage liver disease that increasingly require liver transplantation, a significant public health burden in the United States. The liver is an organ that is constantly exposed to a wide range of immunomodulators, environmental toxins, and gut microbial metabolites through the portal vein. To ensure upkeep of immune tolerance to self and foreign antigens, the liver has a unique immunotolerance mechanism. Heightened immunotolerance or immune permissive microenvironment may create a setting with compromised immunosurveillance that promotes the tumor development and growth in the liver. The gut microbiota can produce large quantities of metabolites such as secondary bile acids that have genotoxic and tumor-promoting effect. The gut dysbiosis due to obesity and other metabolic diseases, which are underlying conditions for non-alcoholic fatty liver, alters the metabolism, synthesis, and transport of bile acids, resulting in the change of bile acid pool size and characteristics. The altered bile acids profile can elicit inflammation and cause liver injury, leading to fibrosis and cirrhosis, and eventually hepatocellular carcinoma. We propose prospectively enroll at least 1000 patients with non-alcoholic fatty liver disease with advanced fibrosis assessed by transient elastography at baseline and once every 6 months. All study participants will be longitudinally followed up for the occurrence of hepatocellular carcinoma and end-stage liver disease for up to five years. The specific aims are to determine if immunosuppressive cytokines, altered bile acid profiles, and the gut dysbiosis have significant impact on the risk of developing hepatocellular carcinoma and end-stage liver disease. The findings, if prove our hypotheses, will provide much needed scientific evidence for the development of effective strategy for management and surveillance for patients with non-alcoholic fatty liver disease with a goal to lower its progression to hepatocellular carcinoma and other end-stage liver disease.




An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
Authors: Liang J.X. , Ampuero J. , Niu H. , Imajo K. , Noureddin M. , Behari J. , Lee D.H. , Ehman R.L. , Rorsman F. , Vessby J. , et al. .
Source: Journal of hepatology, 2023 Sep; 79(3), p. 592-604.
EPub date: 2023-04-29.
PMID: 37121437
Related Citations

High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease.
Authors: Yu Y.C. , Paragomi P. , Wang R. , Liang F. , Luu H.N. , Behari J. , Yuan J.M. .
Source: Cancer, 2023-08-01; 129(15), p. 2341-2347.
EPub date: 2023-04-13.
PMID: 37052455
Related Citations

Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Authors: Behari J. , Gougol A. , Wang R. , Luu H.N. , Paragomi P. , Yu Y.C. , Molinari M. , Chopra K. , Malik S.M. , Geller D. , et al. .
Source: Hepatology communications, 2023-07-01; 7(7), .
EPub date: 2023-07-03.
PMID: 37395730
Related Citations

Soluble CD137 and risk of hepatocellular carcinoma: nested case-control studies in cohorts in Shanghai and Singapore.
Authors: Thomas C.E. , Adibi J.J. , Kuipers A.L. , Diergaarde B. , Luu H.N. , Jin A. , Koh W.P. , Gao Y.T. , Adams-Haduch J. , Wang R. , et al. .
Source: British journal of cancer, 2023 Jun; 128(11), p. 2081-2088.
EPub date: 2023-03-28.
PMID: 36977826
Related Citations

Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Authors: Thomas C.E. , Yu Y.C. , Luu H.N. , Wang R. , Paragomi P. , Behari J. , Yuan J.M. .
Source: Cancer medicine, 2023 Feb; 12(3), p. 3589-3600.
EPub date: 2022-09-02.
PMID: 36052483
Related Citations

Needle-free Nonalcoholic Fatty Liver Disease Prognostication: Moving One Step Closer.
Authors: Behari J. .
Source: Gastroenterology, 2022 Oct; 163(4), p. 819-822.
EPub date: 2022-08-06.
PMID: 35944709
Related Citations

Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease.
Authors: Yu Y.C. , Luu H.N. , Wang R. , Thomas C.E. , Glynn N.W. , Youk A.O. , Behari J. , Yuan J.M. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022 Jan; 31(1), p. 230-235.
EPub date: 2021-10-14.
PMID: 34649958
Related Citations